Detection of Plasma BRAF<sup>V600E</sup> Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas

Bo Hyun Kim,<sup>1,2</sup> In Joo Kim,<sup>1,2</sup> Byung Joo Lee,<sup>3</sup> Jin Choon Lee,<sup>3</sup> In Suk Kim,<sup>4</sup> Seong-Jang Kim,<sup>5</sup> Won Jin Kim,<sup>1</sup> Yun Kyung Jeon,<sup>1</sup> Sang Soo Kim,<sup>1</sup> and Yong Ki Kim<sup>6</sup>

<sup>1</sup>Department of Internal Medicine, School of Medicine, Pusan National University and <sup>2</sup>Biomedical Research Institute, Busan; Departments of <sup>3</sup>Otolaryngology, <sup>4</sup>Laboratory Medicine, and <sup>5</sup>Nuclear Medicine, School of Medicine, Pusan National University, Busan; <sup>6</sup>Kim Yong Ki Internal Medicine Clinic, Busan, Korea.

Received: April 3, 2014
Revised: June 18, 2014
Accepted: July 23, 2014
Corresponding author: Dr. In Joo Kim, Department of Internal Medicine, School of Medicine, Pusan National University, 179 Gudeok-ro, Seo-gu, Busan 602-739, Korea. Tel: 82-51-240-7224, Fax: 82-51-254-3237 E-mail: injkim@pusan.ac.kr

- The authors have no financial conflicts of interest.

Purpose: The BRAF<sup>V600E</sup> mutation represents a novel indicator of the progression and aggressiveness of papillary thyroid carcinoma (PTC). The purpose of this study was to determine the clinical significance of free circulating mutant BRAF<sup>V600E</sup> in predicting the advanced disease of PTC. Materials and Methods: Seventy seven matched tumor and plasma samples obtained from patients with both benign and PTC were analyzed for BRAF<sup>V600E</sup> mutation using a peptide nucleic acid (PNA) clamp real-time polymerase chain reaction (PCR). Results: The BRAF<sup>V600E</sup> mutation was absent in tumor DNA samples obtained from patients with benign and PTC were analyzed for BRAF<sup>V600E</sup> mutation using a peptide nucleic acid (PNA) clamp real-time polymerase chain reaction (PCR). Results: The BRAF<sup>V600E</sup> mutation was absent in tumor DNA samples obtained from patients with benign follicular adenomas or adenomatous goiter. In contrast, 49 of 72 (68.1%) PTC tumors were positive for the BRAF<sup>V600E</sup> mutation. Among them, 3 (6.1%) patients with PTC were positive for BRAF<sup>V600E</sup> mutation in plasma and tumor. However, all 3 patients (100%) had lateral lymph node and lung metastasis. Conclusion: These findings suggest that the BRAF<sup>V600E</sup> mutation can be detected using a PNA clamp real-time PCR in the blood of PTC patients with lung metastasis. Future studies are warranted to determine clinical significance of serum BRAF<sup>V600E</sup> mutation in large prospective studies.

Key Words: BRAF, papillary thyroid carcinoma, plasma, DNA, biomarker

INTRODUCTION

Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumor and comprises about 90% of thyroid malignancies. The overall 10-year survival rate for middle-aged adults with thyroid carcinomas is about 80% to 95% worldwide.<sup>1</sup> However, cervical lymph node metastases are common even when the primary tumor is small and have been reported in up to 90% of patients with PTC.<sup>2,3</sup> Loco-regional recurrences occur in 5% to 20% of patients with PTC. The most common site of recurrence is cervical lymph nodes, which comprise the majority of all recurrences. In many patients, however, lymph node metastases in the central compartment do not appear abnormal preoperatively with imaging such as computed tomography and ultrasonography or by inspection at the time of sur-
gery. In addition, the overall incidence of distant metastases is approximately 10% in patients with PTC. Therefore, it is important to identify patients who are at risk of developing distant metastasis or recurrence that necessitate more aggressive surgical treatment or more intensive radio-active iodine therapy.

A thymidine-to-adenosine transversion at exon 15 nucleotide 1799 (T1799A) of the BRAF gene, resulting in the replacement of valine with glutamic acid at position 600 (BRAFV600E) occurs exclusively in PTC and PTC-derived anaplastic thyroid cancers. The BRAFV600E mutation has been correlated even with PTC recurrence in patients with conventionally low-risk clinicopathological factors. Thus, BRAFV600E mutation represents a novel indicator of the progression and aggressiveness of PTC. Recently, BRAFV600E was detected by allele-specific real-time polymerase chain reaction (PCR) in the blood of PTC patients with residual or metastatic disease and also detectable using a gap-ligase chain reaction technique in the plasma samples from patients with PTC. Therefore, detection of circulating BRAFV600E might allow diagnosis of some PTC patients with a blood test, help to identify patients with unrecognized postoperative minimal residual disease, and prove useful in selection of patients who are at risk of developing distant metastasis or recurrence that necessitate more aggressive treatment.

In Korea, the prevalence of the BRAFV600E mutation in PTC is much higher (73–90%) than that in Western countries. The peptide nucleic acid (PNA)-mediated PCR clamping method is highly sensitive and is efficiently applicable to the detection of BRAF mutations in a clinical setting. Therefore, we have hypothesized that BRAFV600E mutation is more common in peripheral blood in Korean patients with advanced and aggressive PTC and detectable using a PNA clamp real-time PCR. We also evaluated the association of the presence of BRAFV600E mutation with clinicopathologic risk factors for papillary thyroid cancers.

**MATERIALS AND METHODS**

**Ethics statements**

The protocol for the collection of tumor and plasma samples was approved by the Institutional Review Board of Pusan National University Hospital, Busan, Korea (Number: 2011161). Peripheral bloods were obtained preoperatively after written informed consent was obtained. The biospecimens for this study were provided by the Pusan National University Hospital, a member of the National Biobank of Korea, which is supported by the Ministry of Health, Welfare and Family Affairs. All of the data were securely protected, made available only to investigators and analyzed anonymously.

**Patient population**

Seventy-seven matched tumor and plasma DNA samples from patients with thyroid neoplasms (72 PTCs, 1 follicular adenoma, and 4 adenomatous goiters) were obtained from the tumor bank at the Division of Head and Neck Cancer Research, Department of Otolaryngology Head and Neck Surgery, Pusan National University Hospital. Surgical therapy had been total thyroidectomy and central node or lateral node dissection in patients with PTC. Clinicopathologic features were analyzed retrospectively.

**DNA extraction**

For tissue DNA isolation, a total of fresh thyroid samples including tumor tissues and benign thyroid mass were included in the study, 5 benign and 72 malignant. Briefly, a portion of each lesion was removed on resection, immediately snap frozen in liquid nitrogen and stored at -80°C. DNA was extracted from frozen fresh tissue with QIAamp DNA Mini kits (Qiagen, Valencia, CA, USA), according to the manufacturer’s instructions.

For plasma DNA isolation, two 5 mL-aliquots of peripheral blood were collected in EDTA tubes, transported within one hour to the laboratory and centrifuged twice at 4°C for 10 min (1600 rcf and 14000 rcf; or at 415 g or 1660 g). Plasma was aliquoted into 1.5 mL tubes after centrifugation, and stored at -80°C until genetic analysis. DNA was extracted from 500 μL of plasma, using the MinElute Virus Vacuum Kit (Qiagen) and RNase digestion to prevent RNA interference during assay reaction. Plasma DNA was extracted with the QIAamp DNA Blood Midi Kit (Qiagen) according to the manufacturer’s instructions. The extracted DNA yields were similar in the respective tumor and plasma specimens.

**PNA-mediated clamping polymerase chain reaction for detection of BRAF**

The assay for the detection of BRAF was carried out with the PNA Clamp™ BRAF Mutation Detection kit (Pangene, Daejeon, Korea) according to the manufacturer’s instructions. Briefly, PCR amplification was performed in a total volume of 20 μL that contained 50 ng of DNA, 13 μL of real-time SYBR Green PCR master mix and each of the
Statistical analysis
The statistical analysis was performed using the SPSS (ver 15.0 for Windows, SPSS Inc., Chicago, IL, USA) software package. Numeric data were expressed as mean±SD. Categorical data were presented as frequency and percentage. Student t-test for testing differences of nominal variables between BRAF positive group and BRAF negative group was performed. Pearson’s chi-square test was used to compare nominal variables of clinicopathologic characteristics between two groups. Statistical significance was defined as a p<0.05.

RESULTS
In this study, 72 matched tumor and plasma DNA samples were obtained. Table 1 summarized characteristics of the study population and tumor status. There were 12 men and 62 women with an average age of 54.7±14.5 years (range, 34–77 years) in PTC group. There were 5 women with an average age of 50.3±14.0 years (range, 30–60 years) in benign thyroid tumor group. Among 72 PTCs which were evaluated for the BRAF mutation status, 49 PTC tumor samples (68.0%) were determined to harbor the BRAF mutation. However, three of these cases who were positive for BRAF mutation in primary tumors had also detectable BRAF mutation in plasma (Fig. 1). Mutational results of PNA clamp real time PCR was confirmed by direct sequencing (Fig. 2). In our study population, therefore, only 6.1% of patients (3/49) diagnosed with PTC contained the BRAF mutation, and had also circulating DNA positive for the BRAF mutation. Clinical data for four patients with lung metastasis and status of BRAF mutation are presented in Table 2, and clinicopathologic data for patients according to BRAF mutation status in tumor tissue DNA are presented in Table 3. The patients with

Table 1. Characteristics of Study Population and Tumor Status

| Pathology        | No. of cases | Age (yrs)     | Female (%) | No. of tumor with BRAF mutation (%) | No. of paired tumor and plasma with BRAF mutation (%) |
|------------------|--------------|---------------|------------|-------------------------------------|------------------------------------------------------|
| PTC (total)      | 72           | 54.7±14.5     | 60 (83.3)  | 49 (68.1)                           | 3 (6.1)                                              |
| Stage I          | 22           | 44.0±15.8     | 18 (81.8)  | 12 (54.5)                           | 0                                                    |
| Stage II         | 1            | 75            | 1 (100)    | 1 (100)                             | 0                                                    |
| Stage III        | 18           | 59.1±8.4      | 16 (88.9)  | 12 (66.7)                           | 0                                                    |
| Stage IVA        | 27           | 58.9±11.3     | 22 (81.5)  | 20 (74.1)                           | 0                                                    |
| Stage IVB        | 4            | 66.0±14.1     | 3 (75.0)   | 4 (100)                             | 3 (75.0)                                             |
| Benign           | 5            | 50.3±14.0     | 5 (100)    | 0                                   | 0                                                    |

No., number; PTC, papillary thyroid carcinoma; Stage, TNM stage.
positive BRAF mutation had bigger tumor size and more advanced TNM stage was compared with the patients with negative BRAF mutation. However, there was no significant difference in extrathyroidal extension, lymph node (LN) metastasis, and multifocality between the two groups.

**DISCUSSION**

In this study, the BRAF\(^{V600E}\) mutation was detected using the peptide nucleic acid-mediated PCR clamping method in the tissue DNA obtained from 68.1% (49/72) and plasma DNA obtained from 6.1% (3/49) of patients diagnosed with PTC. In contrast, patients with benign thyroid neoplasms had no detectable BRAF mutation in the primary tissue or plasma DNA samples. Plasma BRAF\(^{V600E}\) mutation was detected in three patients with lung metastasis.

PTC is associated with an excellent prognosis compared with other cancers. In addition, PTC typically has a prolonged disease course and is asymptomatic for long periods. However, regional lymph node metastases are frequently detected at diagnosis ranging from 20 to 90%. Cervical lymph node metastases have a poor prognostic factor on survival in patients with follicular thyroid carcinoma (FTC) and in patients with PTC over 45 years.\(^{14}\) Also, about 10% of patients with papillary carcinoma and up to 25% of those with FTC develop distant metastasis or tumor invades the neck aggressively, half of which are present at the time of diagnosis.\(^{15}\) Therefore, it is crucial to identify patients who are at risk of developing distant metastasis or loco-regional recurrence that necessitate more aggressive therapy. In view of this, more convenient and reliable biomarkers are needed to identify high risk patients.

Association of BRAF\(^{V600E}\) mutation with aggressive clinicopathologic characteristics and high tumor recurrence has been demonstrated, although the results are controversial.\(^{16-21}\) BRAF\(^{V600E}\) mutation represents a novel indicator of the progression and aggressiveness of PTC.\(^{7,22}\) Therefore, detection of circulating BRAF\(^{V600E}\) mutation in the blood could determine if patients are disease-free or if they still harbor residual disease. Also, BRAF\(^{V600E}\) mutation status in the blood may be useful biomarkers for selection of patients with residual and recurrent disease for radioactive iodine remnant ablation, radioactive iodine therapy, or other adjuvant treatments, especially in a situation in which a patient had a positive anti-thyroglobulin (Tg) antibody.

Recently, BRAF\(^{V600E}\) mutation was detected in the blood of PTC patients with residual or metastatic disease by allele-specific real-time PCR\(^{8}\) and gap-ligase chain reaction technique.\(^{9}\) Cradic, et al.\(^{8}\) reported that circulating BRAF\(^{V600E}\) mutation was detected in 20 of 173 PTC patients (11.6%), and that BRAF\(^{V600E}\) mutation positivity in blood correlated
with the presence of active disease at the time of the blood draw. Chuang, et al.\textsuperscript{9} also demonstrated that 3 of 5 patients (60\%) with PTC were positive for BRAF\textsuperscript{V600E} mutation in serum and tumor. The results in the present study were consistent with previous studies showing that this plasma BRAF\textsuperscript{V600E} mutation was found only in PTC.\textsuperscript{8,9}

It is well known that high iodine intake is a risk factor for BRAF\textsuperscript{V600E} mutation.\textsuperscript{23} In Korea, dietary iodine intake seems to be higher than in other countries.\textsuperscript{24} The prevalence of the BRAF\textsuperscript{V600E} mutation in PTC is much higher (73\textendash 90\%) than that in Western countries.\textsuperscript{10\textendash 12} The prevalence of BRAF\textsuperscript{V600E} mutation in tumor tissue was 49 of 72 PTC patients (68.1\%), which was consistent with previous Korean data.\textsuperscript{10\textendash 12} PNA clamp technology is the PNA-based PCR clamping that selectively amplifies only the mutated target DNA sequence in the presence of wild type DNAs. Also, PNA-based clamp method has no nonspecific amplifications of DNAs. Thus, it is very useful to detect low-level mutant DNAs.\textsuperscript{12,13} Recently, PNA-mediated PCR clamping method was found to be highly sensitive and efficiently applicable to the detection of BRAF in patients with PTC.\textsuperscript{12,25} Jeong, et al.\textsuperscript{12} reported that the PNA clamp real-time PCR method for the BRAF\textsuperscript{V600E} mutation detection was sensitive in comparison to sequencing. They found that the delta Ct value of the 0.5\% mutant was larger than the cutoff value of 2.0 and the kit sensitively detected 0.5\% mutation. For the sequencing, an automatic reading detected 20\% of the mutant in the background of the wild type. In addition, Kang, et al.\textsuperscript{25} recently reported that pyrosequencing using Food and Drug Administration (FDA) approved method and PNA clamping PCR detected mutant type in a 99:1 (wild-type:mutant) DNA concentration, and PNA-clamping PCR detected mutant type in a 99.5:0.5 DNA concentration for the detection of BRAF\textsuperscript{V600E} mutation with thyroid tissue. PNA clamping PCR showed higher κ value than allele specific real-time PCR. This study suggested that PNA clamping PCR was a sensitive and reliable method to detect the BRAF\textsuperscript{V600E} mutation.

Thus, we have expected higher positivity of plasma BRAF\textsuperscript{V600E} mutation in patient with advanced papillary thyroid carcinoma. However, the current study showed only 3 of 49 patients (6.1\%) with plasma positive for the BRAF\textsuperscript{V600E} mutation. In the present study, although the number of patients is small plasma BRAF\textsuperscript{V600E} mutation positivity was associated with lung metastasis in patients with PTC. In addition, among 31 patients with lateral LNM (N1b), plasma BRAF mutation was detected in 3 patients with lung metastasis. Thus, plasma BRAF mutation might be useful for predic-

| Table 2. Clinical Characteristics of Patients with Distant Metastasis and BRAF Mutation Status in Plasma DNA |
| --- |
| Age (Years) | Sex | BRAF mutation status in plasma | Tumor size and description | LN metastasis | Detection method of distant metastasis | Distal metastasis | Detection method of plasma BRAF mutation |
| 77 | Female | V600E | 3.2 cm, multifocal with ETE | Central and lateral LN | Central and lateral LN | FU chest CT |
| 53 | Female | V600E | 3.0 cm, multifocal with ETE | Central and lateral LN | Central and lateral LN | Preoperative PET-CT |
| 67 | Female | V600E | 2.1 cm, with ETE | Central and lateral LN | Central and lateral LN | Preoperative chest CT |
| 55 | Male | Wild type | 2.5 cm, multifocal with ETE | Central and lateral LN | Central and lateral LN | Diagnostic 1\textsuperscript{1\textendash 1} WBS |

CT, computed tomography; ETE, extrathyroidal extension; FU, follow-up; LN, lymph node; PET, positron emission tomography; RAI, radioactive iodine; Tg, thyroglobulin; T, treatment; WBS, whole body scan.

Reference range of anti-Tg antibody: 0\textendash 60 U/mL.
Plasma BRAF Mutation in Papillary Thyroid Carcinoma

Table 3. Comparison between Disease Status and BRAF Mutation in Tumor Tissue

| Variables                | BRAF mutation positive (n=49) | BRAF mutation negative (n=23) | p value |
|--------------------------|------------------------------|------------------------------|---------|
| Age (yrs)*               | 57.2±11.9                    | 51.3±15.6                    | 0.103   |
| Size (cm)*               | 1.85±0.82                    | 1.35±1.1                     | 0.043   |
| Extrathyroidal extension (%)† | 30 (61.2)                   | 13 (56.5)                    | 0.269   |
| LN metastasis (%)†       | 36 (73.4)                    | 14 (60.9)                    | 0.192   |
| Lateral LN metastasis (%)† | 24 (39.7)                   | 6 (26.1)                     | 0.110   |
| Advanced Stage (%)†      | 32 (65.3)                    | 9 (39.1)                     | 0.022   |
| Multifocality (%)†       | 24 (48.9)                    | 8 (34.8)                     | 0.279   |

n, number; SD, standard deviation; LN, lymph node.
Advanced stage: stage III+stage IV. Data are expressed as means±SD for continuous variables and frequency (%) for categorical variables.
*Student t-test.
†Chi-square test.

BRAF<sup>V600E</sup> positivity in blood seems to be correlated with active disease at the time of the blood draw. Among 4 patients with stage IV C, the initial pathologic stage of a patient with negative plasma BRAF<sup>V600E</sup> mutation was pT3N1bMx, stage IV A. However, this patient (a 55-year-old man) underwent diagnostic <sup>131</sup>I whole body scan (WBS) and stimulated Tg 1 year after iodine ablation therapy. <sup>131</sup>I WBS showed minimal diffuse uptake in both lung fields, and chest CT showed micronodular lung metastasis in both lung fields. Thus, we regarded this patient as final TNM stage IV C. Thyroid tumor tissue and plasma samples of this patient were collected at initial surgery. However, circulating DNA was not extracted on the day of the draw. Although the reason for this has not clear, the lower prevalence of serum BRAF<sup>V600E</sup> mutation in this study might be explained by different analytical method in the detection of BRAF<sup>V600E</sup> mutation, the time interval between extraction of circulating DNA and blood draw, minimal disease activity at the time of the blood sampling, and small sample size. Thus, these results in our study should be further elucidated in future large prospective studies.

BRAF<sup>V600E</sup> mutation in PTC has been shown to correlate with aggressive clinicopathologic characteristics and poor outcomes.16-20 In the current study, the patients with positive BRAF mutation had bigger tumor size and more advanced TNM stage than the patients with negative BRAF mutation. However, previous reports indicated no significant difference in extrathyroidal extension, LN metastasis, and multifocality between the two groups.26-28 We think that the lack of association between the BRAF<sup>V600E</sup> mutation and some poor clinicopathologic factors might have resulted from the small number of cases and/or large number of micro-PTCs (28 of 72, 38.9%), and different prevalence of BRAF<sup>V600E</sup> mutation. Therefore, further studies with a larger patient population may be necessary to determine clinical utilities such as diagnosis and prognosis in patients with PTC.

In conclusion, this study demonstrated that circulating DNA harboring the BRAF<sup>V600E</sup> mutation was detected in patients with PTC by PNA-mediated PCR clamping method. Although the number of patient is small, the current study showed that detection of plasma BRAF<sup>V600E</sup> mutation was associated with lung metastasis. These results suggest the possibility of circulating BRAF mutation as a biomarker in the detection of advanced thyroid cancer. Further investigation for the clinical significance of detecting the BRAF<sup>V600E</sup> mutation in the blood of patients with PTC is warranted.

ACKNOWLEDGEMENTS

The biospecimens for this study were provided by the Pusan National University Hospital, a member of the National Biobank of Korea, and the study was supported by the Ministry of Health, Welfare and Family Affairs. All samples derived from the National Biobank of Korea were obtained with informed consent under Institutional Review Board-approved protocols.

REFERENCES

1. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000;6:469-76.
2. Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996;5:43-63.
3. Machens A, Hinze R, Thomusch O, Dralle H. Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002;26:22-8.
4. Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, et al. Value of preoperative ultrasonography in the
surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 2006;141:489-94.
5. Shaha AR, Ferlito A, Rinaldo A. Distant metastases from thyroid and parathyroid cancer. ORL J Otorhinolaryngol Relat Spec 2001;63:243-9.
6. Benbassat CA, Mechlis-Fris S, Hirsch D. Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg 2006;30:1088-95.
7. Liu D, Liu Z, Condouris S, Xing M. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab 2007;92:2264-71.
8. Cradic KW, Milosevic D, Rosenberg AM, Erickson LA, McIver B, Grebe SK. Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab 2009;94:5001-9.
9. Chuang TC, Chuang AY, Poeta L, Koch WM, Califano JA, Tufano RP. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck 2010;32:229-34.
10. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004;45:818-21.
11. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006;65:364-8.
12. Jeong D, Jeong Y, Park JH, Han SW, Kim SY, Kim YJ, et al. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR. Ann Surg Oncol 2013;20:759-66.
13. Kwon MJ, Lee SE, Kang SY, Choi YL. Frequency of KRAS, BRAF, and PIK3CA mutations in advanced colorectal cancers: comparison of peptide nucleic acid-mediated PCR clamping and direct sequencing in formalin-fixed, paraffin-embedded tissue. Pathol Res Pract 2011;207:762-8.
14. Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery 2008;144:1070-7.
15. Mazzaferrri EL. Management of a solitary thyroid nodule. N Engl J Med 1993;328:553-9.
16. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 2006;13:257-69.
17. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008;93:3943-9.
18. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minato M, et al. Association of BRAF mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:4085-90.
19. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007;110:38-46.
20. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246:466-70.
21. Trovisco V, Couto JP, Cameselle-Teijeiro J, de Castro IV, Fonseca E, Soares P, et al. Acquisition of BRAF gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2008;69:683-5.
22. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-62.
23. Guan H, Ji M, Bao R, Yu H, Wang Y, Hou P, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 2009;94:1612-7.
24. Kim JY, Moon SJ, Kim KR, Sohn CY, Oh JJ. Dietary iodine intake and urinary iodine excretion in normal Korean adults. Yonsei Med J 1998;39:355-62.
25. Kang SH, Pyo JY, Yang SW, Hong SW. Detection of BRAF V600E mutation with thyroid tissue using pyrosequencing: comparison with PNA-clamping and real-time PCR. Am J Clin Pathol 2013;139:759-64.
26. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005;63:588-93.
27. Rha SY, Lee JC, Kwon KH, Lee HJ, Kim KS, Jo YS, et al. The relationship between the BRAF mutations in thyroid papillary carcinomas and the prognostic factors. J Korean Soc Endocrinol 2005;20:224-9.
28. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch 2005;446:589-95.